Drug Trial Radar · NCT03733990
A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS)
Last checked: Nov 19, 2026Latest source record: Apr 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
216
Actual
Start
Dec 3, 2018
Primary completion
Sep 6, 2023
Study completion Oct 31, 2023
Sponsor
- Lead sponsor
- Faron Pharmaceuticals LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first in human study to identify whether FP-1305 is suitable to use in humans. The previous pre-clinical studies have demonstrated that FP-1305 binds to a receptor known as CLEVER-1. CLEVER-1 has been shown to support tumour growth. No significant adverse events were witnessed in primates and the dose used will be 300 fold lower than the dose provided to primates which showed no toxicity. The patients with advanced melanoma, uveal melanoma, cholangiocarcinoma, gallbladder cancer, ER+ breast, gastric, ovarian, pancreatic, colorectal, liver or anaplastic thyroid cancer who have exhausted all licenced therapeutic options will die due to their disease. Based on the investigator's existing data CLEVER-1 is expressed in these tumour types. Inhibition of CLEVER-1 with FP-1305 may have an anti-tumour effect in these patients.
Conditions
- Cancer
Interventions
FP-1305 (bexmarilimab)Biological
The study will test for the first time in patients with cancer, an experimental medicine, called FP-1305. The study goal is to find the dose of FP-1305 that works best against cancer while it remains safe for use, tolerable and effective in patients with cancer.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT) in the Trial Subjects.Time frame: Up to one year
- Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)Time frame: approximately 4 years and 9 months
- The Response Objective Response Rate (ORR) to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.Time frame: approximately 4 years and 9 months
- The Disease Control Rate (DCR) Response to the Treatment Was Planned to be Determined by Tumor Imaging According to RECIST 1.1.Time frame: approximately 4 years and 9 months
Locations
11 sites in 6 countries. Site status is shown where the registry gives one.
The University of Texas Health Science Center at San Antonio
San Antonio, Texas
Clinical Research Institute HUCH Ltd
Helsinki, Finland
Oulu University Hospital
Oulu, Finland
Tampere University Hospital
Tampere, Finland
Turku University Hospital
Turku, Finland
The Institut Gustave Roussy
Villejuif, France
Erasmus University Medical Center Rotterdam
Rotterdam, Netherlands
START Madrid - CIOCC Hospital HM Sanchinarro
Madrid, Spain
Queen Elizabeth Hospital Birmingham
Birmingham, United Kingdom
The Christie NHS Foundation Trust
Manchester, United Kingdom
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.